Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.
Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...
The English version of this publication updated 2024. Please refer to the earlier versions on this page if you need languages other than English. English version updated April 2020. The updated guide reflects new information from recently completed clinical…
Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).
Treatment Action Group (TAG) is urging caution regarding the use of antiretroviral (ART) drugs as treatments for SARS-CoV-2/COVID-19. While there is clearly an acute need to carefully and quickly study interventions that may have activity against SARS-CoV-2, the virus which causes COVID-19 disease, it’s vitally important to be aware of the information that is currently available.
Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.
A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.
An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.
The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.